nyra health: € 20 million in Series A for AI-supported neurotherapy

Vienna — The digi­tal health company nyra health, a leading provi­der of an AI-based plat­form for neuro­lo­gi­cal therapy, announ­ces the successful closing of a Series A finan­cing of EUR 20 million. The round is led by Armira Growth, with exis­ting inves­tors Welling­ton Part­ners, Crane Venture Part­ners (who manage the invest­ments of Mass­Mu­tual Ventures) and EVER Pharma parti­ci­pa­ting again. The capi­tal will be used for inter­na­tio­nal expan­sion, product deve­lo­p­ment and the expan­sion of the AI-based neuro­the­rapy platform. 

The core product is the MDR Class IIa-certi­­fied “myReha” plat­form, which accor­ding to the company is alre­ady being used in over 100 neuro­lo­gi­cal clinics. In addi­tion, the appli­ca­tion is part of the stan­dard care provi­ded by Deut­sche Renten­ver­si­che­rung and is reim­bur­sed by 28 statu­tory and private health insu­rance compa­nies. More than 40 million insu­red persons thus have access to digi­tal neuro-rehabilitation. 

Inte­gra­tion into inpa­ti­ent and outpa­ti­ent care proces­ses is parti­cu­larly rele­vant for hospi­tal manage­ment. nyra health addres­ses the frequently criti­ci­zed gap in care between discharge from an acute or reha­bi­li­ta­tion clinic and outpa­ti­ent after­care. The plat­form connects pati­ents and health­care profes­sio­nals digi­tally throug­hout the entire reco­very process. In addi­tion to the “myReha” therapy soft­ware, the offe­ring includes the “nyra insights” manage­ment system, which maps therapy inten­sity, language deve­lo­p­ment and progress data in real time and auto­ma­tes docu­men­ta­tion processes. 

Stron­ger impro­ve­ments in cogni­tive and lingu­i­stic functions 

Accor­ding to the company, a rando­mi­zed control­led study shows signi­fi­cantly grea­ter impro­ve­ments in cogni­tive and lingu­i­stic func­tions with addi­tio­nal use of the plat­form compared to stan­dard therapy. The multi­mo­dal AI models analyze pronun­cia­tion, word retrie­val, syntax and seman­tic struc­ture as well as reac­tion times and trai­ning dyna­mics, among other things. The therapy adapts adap­tively to perfor­mance level and progress. 

In terms of health econo­mics, the model addres­ses the rising costs of neuro­lo­gi­cal dise­a­ses, for exam­ple after a stroke or trau­ma­tic brain injury. Digi­tal home therapy with real-time feed­back can increase therapy density and at the same time reduce the workload of specia­lists — a key aspect given the scar­city of person­nel resour­ces in neuro-rehabilitation. 

With the finan­cing, nyra health plans to increase its market pene­tra­tion in the DACH region and enter the US market. At the same time, the company is inves­t­ing in the further deve­lo­p­ment of multi­mo­dal AI models, inclu­ding as part of a funded rese­arch project. 

The market is considera­ble: neuro­lo­gi­cal dise­a­ses cost 65 billion euros a year in Germany alone. The increase in neuro­lo­gi­cal dise­a­ses, prima­rily due to the rising average age of the popu­la­tion, offers considera­ble growth potential.